Is docetaxel plus epirubicin versus docetaxel plus capecitabine a more effective combination as a front-line treatment in women with advanced breast cancer?

From: Annals of Oncology

Journal rating:
rating: 98%
Study Quality:
rating: 85%

Overall Reliability

Article Quality:
rating: 65%
rating: 25%


  • 136 previously untreated women with advanced breast cancer


  • Patients were randomly assigned to receive docetaxel 75 mg/m2 plus epirubicin 75 mg/m2 on day 1 or docetaxel 75 mg/m2 on day 1 plus capecitabine 950 mg/m2 orally twice daily on days 1–14 in 21-day cycles.
  • The primary objective of the study was to compare time to disease progression


  • Time to disease progression was 10.6 versus 11.0 months for docetaxel plus epirubicin and docetaxel plus capecitabine respectively.
  • Docetaxel plus epirubicin regimen was relatively more toxic resulting in more neutropenia, anemia, asthenia and toxicity-related hospitalizations versus more hand–foot syndrome and nausea– vomiting with the docetaxel plus capecitabine regimen. 


  • No (with confidence)


Editors Notes

  • The results indicate that the docetaxel plus epirubicin and docetaxel plus capecitabine regimens have similar efficacy but the docetaxel plus capecitabine regimen is favored because of less non-hematological toxicity.